| scholarly article | Q13442814 |
| P50 | author | Hideho Okada | Q90417075 |
| P2093 | author name string | Neil Hoa | |
| German G Gomez | |||
| Wenxue Ma | |||
| Boris Minev | |||
| Carol A Kruse | |||
| Jian Gang Zhang | |||
| Martin R Jadus | |||
| Christina Delgado | |||
| H Terry Wepsic | |||
| Junichi Eguchi | |||
| Stephanie Schroter | |||
| Habib Fakhrai | |||
| P2860 | cites work | Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers | Q48276012 |
| T9 glioma cells expressing membrane-macrophage colony stimulating factor produce CD4+ T cell-associated protective immunity against T9 intracranial gliomas and systemic immunity against different syngeneic gliomas | Q48532439 | ||
| Vimentin and glial fibrillary acidic protein in human brain tumors | Q48566565 | ||
| Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study | Q48764632 | ||
| Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. | Q55471967 | ||
| Expression of cancer testis genes in human brain tumors. | Q55475016 | ||
| Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. | Q55475772 | ||
| Beta1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity. | Q55476232 | ||
| Expression of the tumor-rejection antigen SART1 in brain tumors. | Q55476322 | ||
| Detection of MAGE-1 tumor antigen in brain tumor. | Q55478995 | ||
| Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice. | Q55490268 | ||
| Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues | Q71527769 | ||
| Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression | Q72133139 | ||
| MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope | Q73129257 | ||
| Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas | Q24678319 | ||
| A new mathematical model for relative quantification in real-time RT-PCR | Q27860781 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain | Q28201859 | ||
| Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types | Q30724116 | ||
| Identification of a human glioma antigen, SOX6, recognized by patients' sera | Q31033978 | ||
| Glioma immunology and immunotherapy. | Q33891440 | ||
| A listing of human tumor antigens recognized by T cells | Q33943569 | ||
| AIM-2: a novel tumor antigen is expressed and presented by human glioma cells | Q34312425 | ||
| Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine | Q35682709 | ||
| Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes | Q36363449 | ||
| Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma | Q36613456 | ||
| Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas | Q36649125 | ||
| Intracellular localization of cyclin B1 during the cell cycle in glioma cells | Q36809406 | ||
| Patterns of antigenic expression of human glioma cells | Q37430142 | ||
| EphA2 as a novel molecular marker and target in glioblastoma multiforme | Q40357219 | ||
| EphA2 as a glioma-associated antigen: a novel target for glioma vaccines | Q40365151 | ||
| Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment | Q40400501 | ||
| HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells | Q40534809 | ||
| Adoptive cellular immunotherapy for the treatment of malignant gliomas | Q40601126 | ||
| T cell adoptive immunotherapy of newly diagnosed gliomas | Q40619438 | ||
| Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway | Q41365006 | ||
| Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1. | Q41755185 | ||
| Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma | Q42171716 | ||
| Quantitatively determined survivin expression levels are of prognostic value in human gliomas | Q43886332 | ||
| Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma | Q44980797 | ||
| Human U251MG glioma cells expressing the membrane form of macrophage colony-stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression o | Q46039988 | ||
| Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination | Q46666471 | ||
| Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration | Q46720423 | ||
| Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. | Q47999142 | ||
| P433 | issue | 2 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 566-575 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics | |
| P478 | volume | 13 |
| Q38858547 | "Stealth" melanoma cells in histology-negative sentinel lymph nodes. |
| Q93133060 | A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials |
| Q38227889 | A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy |
| Q27030863 | Adoptive cell therapies for glioblastoma |
| Q47142436 | Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma |
| Q46345741 | Bladder polypoid cystitis-derived A20 associates with tumorigenesis |
| Q37580419 | Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99. |
| Q91670709 | CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy |
| Q39358663 | Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma |
| Q37851972 | Cellular Immunotherapy for High-Grade Glioma |
| Q34243550 | Cellular and vaccine therapeutic approaches for gliomas |
| Q27014912 | Cellular immunotherapy for pediatric solid tumors |
| Q35821404 | Cellular-based immunotherapies for patients with glioblastoma multiforme. |
| Q41336790 | Changes in tumor-antigen expression profile as human small-cell lung cancers progress |
| Q39111239 | Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. |
| Q36597942 | Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients |
| Q64118505 | Current State of Immunotherapy for Treatment of Glioblastoma |
| Q26828965 | Current vaccine trials in glioblastoma: a review |
| Q34983788 | Cytotoxic T-cells as imaging probes for detecting glioma |
| Q36899104 | Dendritic cell vaccination |
| Q34407938 | Differential Glioma-Associated Tumor Antigen Expression Profiles of Human Glioma Cells Grown in Hypoxia |
| Q55466649 | Drug cocktails for effective treatment of glioblastoma multiforme. |
| Q37778052 | Drug or vaccine?: selecting the appropriate treatment for malignant glioma patients |
| Q37025105 | Emerging immunotherapies for glioblastoma |
| Q38997973 | Eph Receptor Tyrosine Kinases in Tumor Immunity |
| Q37965751 | Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. |
| Q39686208 | Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity |
| Q24615166 | Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma |
| Q61811641 | Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy |
| Q38178690 | Genetically modified T cells to target glioblastoma |
| Q36393422 | Glioma big potassium channel expression in human cancers and possible T cell epitopes for their immunotherapy |
| Q33999299 | Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma. |
| Q33779140 | HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma |
| Q41783221 | HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors |
| Q42141424 | High frequency of T cells specific for cryptic epitopes in melanoma patients |
| Q39970401 | Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy |
| Q37435455 | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas |
| Q37420586 | Immune-checkpoint blockade and active immunotherapy for glioma |
| Q33740546 | Immunobiological characterization of cancer stem cells isolated from glioblastoma patients |
| Q38870994 | Immunological Aspects of Malignant Gliomas |
| Q37267793 | Immunotherapeutic approaches for glioma |
| Q37925259 | Immunotherapy in human glioblastoma |
| Q34701587 | Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions |
| Q34140756 | Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells |
| Q37608106 | Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper |
| Q40985735 | Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas |
| Q52683991 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). |
| Q38953024 | Improving vaccine efficacy against malignant glioma |
| Q28389458 | In vitro enhancement of dendritic cell-mediated anti-glioma immune response by graphene oxide |
| Q47771059 | Industry progress report on neuro-oncology: Biotech update 2013. |
| Q34177641 | Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. |
| Q45879220 | Interleukin-13 receptor α2: glioma's unlucky receptor? |
| Q50124620 | Limiting glioma development by photodynamic therapy-generated macrophage vaccine and allo-stimulation: an in vivo histological study in rats |
| Q34102273 | Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma |
| Q61811189 | Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma |
| Q34870511 | Molecular alterations in glioblastoma: potential targets for immunotherapy |
| Q48242886 | Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy |
| Q35878535 | Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain |
| Q46512368 | Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy |
| Q36523499 | Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma |
| Q34594769 | Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy |
| Q35955393 | Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients |
| Q37239071 | Recent advances and future of immunotherapy for glioblastoma |
| Q40729879 | Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease |
| Q39258646 | T cells redirected to EphA2 for the immunotherapy of glioblastoma |
| Q37137932 | Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape |
| Q38760726 | Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy |
| Q36950556 | The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting |
| Q44004603 | The detection of CMV pp65 and IE1 in glioblastoma multiforme |
| Q38255481 | The future of glioblastoma therapy: synergism of standard of care and immunotherapy |
| Q37533657 | Toward effective immunotherapy for the treatment of malignant brain tumors |
| Q42696122 | Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma |
| Q37734481 | Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy |
| Q89965816 | Tumor-Specific T Cell Activation in Malignant Brain Tumors |
| Q64913238 | Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma. |
| Q35799695 | Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. |
Search more.